Analyst Price Targets — MPLT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 10, 2026 11:04 am | — | Needham | $45.00 | $39.80 | StreetInsider | MapLight Therapeutics (MPLT) PT Raised to $45 at NeedhamMember Login |
| June 24, 2026 8:29 pm | — | Raymond James | $46.00 | $30.65 | TheFly | MapLight Therapeutics initiated with a Strong Buy at Raymond James |
| June 23, 2026 12:44 pm | — | Craig-Hallum | $40.00 | $29.94 | TheFly | MapLight Therapeutics price target lowered to $40 from $43 at Craig-Hallum |
| June 1, 2026 8:13 pm | Paul Matteis | Stifel Nicolaus | $36.00 | $29.76 | StreetInsider | MapLight Therapeutics (MPLT) PT Raised to $36 at Stifel |
| May 26, 2026 8:17 pm | Ashwani Verma | UBS | $48.00 | $29.46 | TheFly | MapLight Therapeutics initiated with a Buy at UBS |
| May 21, 2026 11:20 am | Adam Vogel | Craig-Hallum | $43.00 | $27.81 | TheFly | MapLight Therapeutics initiated with a Buy at Craig-Hallum |
| May 4, 2026 10:12 am | Raghuram Selvaraju | H.C. Wainwright | $45.00 | $30.70 | TheFly | MapLight Therapeutics initiated with a Buy at H.C. Wainwright |
| November 21, 2025 12:34 pm | Marc Goodman | Leerink Partners | $30.00 | $13.29 | TheFly | MapLight Therapeutics initiated with an Outperform at Leerink |
| November 21, 2025 10:07 am | Andrew Tsai | Jefferies | $32.00 | $13.29 | TheFly | MapLight Therapeutics initiated with a Buy at Jefferies |
| November 21, 2025 10:05 am | — | Stifel Nicolaus | $28.00 | $13.29 | TheFly | MapLight Therapeutics initiated with a Buy at Stifel |
Latest News for MPLT
SAN FRANCISCO and BOSTON, June 24, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system (CNS) disorders, today announced the appointment of Martin Babler and Troy Cox to its Board of Directors following their election at the Company's Annual Meeting of Stockholders…
MapLight Therapeutics, Inc. (MPLT) Discusses Top Line Phase II IRIS Study Results for ML-004 in Autism Spectrum Disorder Transcript
MapLight Therapeutics Inc. (NASDAQ:MPLT) reported mixed topline results from its Phase 2 IRIS study of ML-004 in patients with autism spectrum disorder.
SAN FRANCISCO and BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today announced topline results from IRIS (ML-004-002), a Phase 2 study of ML-004 in autism spectrum disorder (ASD). The study randomized 161 participants (102…
Enrollment completed in ML-007C-MA's Phase 2 ZEPHYR trial in schizophrenia, with topline results expected by mid-August 2026 Last patient visit completed for ML-004's Phase 2 IRIS trial in autism spectrum disorder, with topline results expected by mid-August 2026 Enrollment ongoing in ML-007C-MA's Phase 2 VISTA trial in Alzheimer's disease psychosis, with topline results expected in the second half of 2027 Ended the…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for MPLT.
Senate Trading
No Senate trades found for MPLT.
U.S. House Trading
No House trades found for MPLT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.